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introduction
Treatment of locoregionally advanced head and neck squamous cell carcinoma (HNSCC) requires multimodality therapy, including definitive chemoradiation therapy (CRT) or surgery with adjuvant therapy for high-risk pathologic features. Definitive CRT has gained popularity due to increasing prioritization of organ preservation with multiple series demonstrating favorable outcomes [1] [2] [3] . CRT with concurrent cisplatin is the standard of care for the treatment of locoregionally advanced disease [4] . Our institutional experience with hyperfractionated CRT and combination chemotherapy has demonstrated promising clinical outcomes in serial trials [5] [6] [7] [8] [9] [10] [11] [12] . Induction chemotherapy (IC) has been investigated in patients at high risk of distant disease. The addition of docetaxel to cisplatin and 5-FU IC has demonstrated an overall survival (OS) benefit [13] [14] [15] . However, trials randomizing patients to definitive treatment with or without IC have been negative [12, 16] .
Increasing efforts have focused upon stratifying this diverse disease into treatment paradigms based on causative factors and high-risk factors. Human papillomavirus (HPV) has emerged as a causative agent for oropharyngeal (OP) cancers [17] . Examination of US population-based cancer registries demonstrates an increasing incidence of HPV-positive OP SCC from 16.3% in 1984-1989 to 71.7% in 2000-2004 [18] . Concurrently, non-OP cancer incidence has remained stable to decreasing, possibly secondary to decreased tobacco use [19] [20] [21] [22] . HPV positivity is a positive prognostic factor with improved OS, progression-free survival, and responsiveness to chemoradiotherapy [23] [24] [25] . Favorable prognostic factors that are often present in HPV-positive patients, such as young age, account for ∼10% of this improvement [23] .
OS for HNSCC has improved for all stages of disease, co-incident with HPV epidemic data [26] . However, it is not known whether these improvements are a result of improved treatments of all HNSCC, including HPV-negative HNSCC, or whether these improvements are merely a result of increasing incidence of HPV-positive HNSCC. The current analysis compares the clinical outcomes of OP and non-OP patients over a series of seven institutional, non-randomized and randomized, prospective trials.
patients and methods
We reviewed all patients with HNSCC treated at a single institution on a series of prospective trials from 1993 to 2010 (Table 1) . For this analysis, we included patients diagnosed with pathologically proven HNSCC, including oral cavity, oropharynx, hypopharynx, and larynx primary sites. All patients had stage IV disease except for a single patient with stage III disease. All patients were treated by a multidisciplinary team, including medical original articles Annals of Oncology oncology, radiation oncology, and surgical oncology. Pre-treatment evaluation included history and physical, panendoscopy, and radiographic assessment of primary tumor, neck, and chest with computerized tomography (CT). Positron emission tomography (PET) was allowed but not required. All patients received CRT. Patients with a prior history of head and neck radiation therapy were excluded. Organ-preserving surgery was allowed before definitive therapy. Patients signed institutional review board approved informed consent before initiation of therapy. For the purposes of retrospective comparison, patients were divided into three groups before data analysis according to the time period during which they were treated. Groups 1, 2, and 3 were treated between 1993-1998, 1999-2003 and 2004-2010 , respectively. Trends were subsequently compared for OP and non-OP patients.
induction chemotherapy IC was included on four of the seven prospective trials (Table 1) . IC regimens were taxane and carboplatin-based and lasted between 6 and 8 weeks.
concurrent chemotherapy
All protocols included CRT ( Table 1 ). The most common regimen was five cycles of CRT with paclitaxel, 5-fluorouracil, and hydroxyurea.
radiation therapy
Patients underwent CT-based planning with delineation of risk-defined contours. Diagnostic imaging (CT, MRI, and PET) were fused to assist in contouring as clinically indicated. Sequential plans were created for low (36-45 Gy), intermediate (51-60 Gy), and high-risk volumes (65-75 Gy). Radiation was administered twice daily for five consecutive days with cycles every 14 days except for Arm 2 of EPIC which included accelerated RT with concomitant boost (Table 1) .
statistical evaluation
OS, recurrence-free survival (RFS), and distant failure-free survival (DFFS) were estimated using the Kaplan-Meier method [27] . All outcomes were defined from the date enrolled on institutional clinical protocol. RFS was the time from enrollment until recurrence at any site or death from any cause. DFFS was time from enrollment until distant recurrence or death from any cause. Logrank tests were utilized to assess for differences between survival curves across the three time periods. The Cox [28] proportional hazards models were fit for OS, RFS, and DFFS to compare the three time periods adjusted for baseline prognostic factors. Variables included in the multivariable model were age, performance status (PS), smoking history, T-stage, N-stage, and treatment period. [2004] [2005] [2006] [2007] [2008] [2009] [2010] in the OP subset. The time-to-event curves were significantly different after adjusting for baseline covariates (P = 0.017). The non-OP 5-year RFS was 42.9%, 53.6%, and 61.7% for the same time periods (adjusted P = 0.30).
overall survival
OS improved over the course of the three examined time periods for both OP and non-OP patients with only OP trends reaching statistical significance (adjusted P = 0.0084; Figure 2 ). [26] . Because our data demonstrate that improved clinical outcomes only reached statistical significant in our OP subset, the most likely contributing factor is the increasing incidence of HPV-positive tumors. The increasing incidence of HPV-positive tumors shown by Chaturvedi et al. [18] supports this conclusion. Although therapeutic advances may also contribute to these improvements, we would expect that OP and non-OP patients would experience similar improvements when given the same regimen if the therapeutic interventions were primarily responsible.
Increasingly sensitive staging studies and resultant stage migration may also contribute to the observed improvements in outcomes. FDG-PET/CT has been shown to be superior to CT alone for regional [32] and metastatic staging [33] . In our study, the percentage of early nodal stage has decreased from 14.6% to 2% (for N0) and 11.2% to 3.4% (for N1). Other studies have similarly demonstrated an overall increase in locoregionally advanced cancers from 1974 to 1999 [29] . This may be at least partially attributable to the fact that HPV-positive cancers often present with smaller primaries and more advanced nodal disease. There has been significant interest in the de-escalation of CRT for HPV-positive tumors. Building upon the prospective trial ECOG 2399, which showed that patients with HPV-positive tumors had improved responses to both IC and definitive CRT as well as improved OS when compared with HPV-negative tumors [34] . ECOG 1308 examined whether lower doses of RT are sufficient for HPV-positive tumors. Eighty patients with resectable, stage III-IV, HPV-positive, OP SCC received three cycles of IC (paclitaxel, cisplatin, and cetuximab) and were evaluated for response with a clinical exam and imaging studies. They subsequently received either 54 Gy in 27 fractions if complete response (62 patients) or 69.3 Gy in 33 fractions (15 patients) if less than a complete response, both with concurrent cetuximab. Preliminary findings of the 54 Gy group demonstrated a 24-month OS of 95%, 23-month PFS of 84%, primary local control of 94%, nodal control of 95%, and distant control of 92%. Notably, they did not reach their primary end point of 85% 2-year PFS for the low-dose arm [35] .
ECOG E-3311 examines de-intensification in the post-operative setting. Patients with stage III-IV (N1-N2b) OP SCC undergo transoral resection and neck dissection followed by risk-stratified further treatment based on their pathologic findings. Respective treatments for low, intermediate, and high-risk features are observation, RT alone, and concurrent CRT with cisplatin.
Our findings support current and future efforts for clinical trial risk-stratification by primary site and HPV status. This study supports the notion that HPV-positive OP SCC may be sufficiently treated by de-intensified treatments, although randomized trials are needed to test this hypothesis. When examining further de-intensification efforts, it is important to consider that ECOG 1308 was a negative study as it did not reach its primary end point. Furthermore, novel definitive treatments may be needed for carcinogen-related malignancies that may not respond as favorably to standard available treatments.
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